Pharmacopeia, Inc. (NASDAQ:PCOP)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $1.74 |
| Daily Range | $1.65 - $1.79 |
| 52-Week Range | $0.59 - $5.59 |
| Market Cap | $51.96M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 0 |
| Average Daily Volume | 0 |
PCOP
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
PCOP Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
PCOP News and Commentary
- Exelixis and Glaxo Begin Their Goodbyes – The Motley Fool
- A Little Bit of Cash for ArQule – The Motley Fool
- No Slowdown for China's WuXi – The Motley Fool
- Array Pushes Ahead – The Motley Fool
- Talking With a Development-Stage Pharma – The Motley Fool
- A Bird in the Hand for Exelixis – The Motley Fool
- An Array of Good News – The Motley Fool
- Discovering Pharmacopeia – The Motley Fool
- 4 Biotech Bets Under $10 – The Motley Fool
- What Drives Accelrys? – The Motley Fool
- The Players and Pretenders of Nanotech – The Motley Fool
- Nano or Bust – The Motley Fool
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
RSS Headlines
Fool UK
